Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researchers find crucial signaling pathway that helps HSCs to generate

Researchers find crucial signaling pathway that helps HSCs to generate

New approach to predict myeloma patients using calcium isotope analysis

New approach to predict myeloma patients using calcium isotope analysis

Epigenetics has a large say in blood formation

Epigenetics has a large say in blood formation

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Scientists solve key mystery in cancer research

Scientists solve key mystery in cancer research

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Research: Tumor-suppressing protein linked with CHARGE syndrome

Research: Tumor-suppressing protein linked with CHARGE syndrome

Researchers identify possible new drug target for treating childhood blood cancer

Researchers identify possible new drug target for treating childhood blood cancer

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

Little-known supportive cells in brain may play major role in cognitive function

Little-known supportive cells in brain may play major role in cognitive function

FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

Lifestyle impacts likelihood of developing metabolic syndrome in childhood cancer survivors

Lifestyle impacts likelihood of developing metabolic syndrome in childhood cancer survivors

EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.